
Xtant Medical Holdings, Inc.
XTNTAMEXHealthcareMedical - Devices
前收盤價
US$0.3249
−US$0.0084 · -2.52%
XTNT公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Hold
Wait — insufficient conviction to act
估值
79
Undervalued
動能
18
Strong Down
情緒
46
Mixed
風險韌性
43
Elevated Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological surgeons both within the United States and globally. Its comprehensive product portfolio is categorized into several key areas: 1. Biomaterial Offerings: This category includes products like OsteoSponge, which provides a natural structural support for cellular growth and introduces vital bone-forming proteins to aid the healing process. OsteoSponge SC is specifically designed to repair bone defects in the subchondral area of joints. Other items are OsteoSelect DBM Putty, fostering osteoinductive bone regeneration, and OsteoSelect PLUS DBM Putty, which functions as a bone void filler and graft substitute for procedures involving the pelvis, extremities, and posterolateral spine. Additionally, the line features OsteoFactor, containing diverse proteins and peptides that facilitate bone formation and remodeling, along with OsteoWrap and OsteoVive Plus, a cellular bone matrix enriched with growth factors. 2. Allograft Technologies: Under the 3Demin brand, Xtant Medical provides a range of allografts (human bone grafts) engineered to maximize both osteoconductivity and osteoinductive capabilities. This includes specialized sports allografts used for repairing anterior and posterior cruciate ligaments, ACL reconstruction, and meniscal repairs. They also offer milled spinal allografts, where cortical bone is precisely shaped to specific dimensions, as well as traditional allografts applicable across numerous medical disciplines such such as orthopedics, neurology, podiatry, oral/maxillofacial surgery, genitourinary, and plastic/reconstructive surgery. 3. Spinal Fixation and Fusion Systems: The company furnishes a variety of sophisticated spinal devices. These include the Certex spinal fixation system, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, the Xpress minimally invasive pedicle screw system, and Fortex Pedicle screw systems. Further systems encompass Calix, for use in cervical and thoracolumbar regions, the Axle-X interspinous fusion system, Irix-C for cervical integrated fusion, and the Irix-A Lumbar integrated fusion system. The company underwent a name change in July 2015, transitioning from its former identity as Bacterin International Holdings, Inc. to Xtant Medical Holdings, Inc.
- 產業
- Medical - Devices
- 部門
- Healthcare
- 總部
- US
- 執行長
- Sean E. Browne
- 上市以來
- 2010年7月1日
- 僱員
- 151
市場位置
日內區間
目前US$0.3249,
52週區間
目前US$0.3249,
- 開盤價
- US$0.34
- 前收盤價
- US$0.3333
- 成交量
- 14.36萬
- 0.96× 平均值
- 平均成交量
- 15.02萬
- 日均成交量
- 市值
- 4557.14萬 USD
- 貝塔
- -0.14
- 市場參考 1
- 50天平均值
- US$0.4126
- 低於平均水平-21.26%
- 200天平均值
- US$0.5524
- 低於平均水平-41.18%
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 1.21億 USD
- 本益比(TTM)
- -3.95×
- 股價淨值比(TTM)
- 1.14×
- 股價營收比(TTM)
- 0.42×
- EV/EBITDA
- 7.62×
- 盈餘收益率
- 4.55%
- 自由現金流收益率
- 9.29%
- 股息率
- 0.00%
獲利能力和效率
- 毛利率
- 59.39%
- 營業利益率
- -9.58%
- 淨利潤率
- -10.17%
- 股東權益報酬率
- 9.76%
- 資產報酬率
- 5.28%
- 投入資本報酬率
- 6.49%
財務健康
- 負債權益比
- 0.65×
- 流動比率
- 2.65×
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.34億 USD | 1.17億 USD | 9130.3萬 USD | 5796.9萬 USD | 5526.3萬 USD |
| 銷貨成本 | 4965.4萬 USD | 4905.1萬 USD | 3583.6萬 USD | 2583.2萬 USD | 2277.3萬 USD |
| 毛利 | 8427.3萬 USD | 6821.6萬 USD | 5546.7萬 USD | 3213.7萬 USD | 3249萬 USD |
| 研究與開發 | 210.2萬 USD | 238.5萬 USD | 133.6萬 USD | 91.5萬 USD | 87萬 USD |
| 銷售、一般及管理費用 | 7488.7萬 USD | 7790.5萬 USD | 6428.9萬 USD | 3797.7萬 USD | 3547.4萬 USD |
| 營業費用 | 7698.9萬 USD | 8029萬 USD | 6562.5萬 USD | 3889.2萬 USD | 3634.4萬 USD |
| 利息收入 | 9.4萬 USD | — | 14.9萬 USD | 3.1萬 USD | — |
| 利息支出 | 367.1萬 USD | 416萬 USD | 293.8萬 USD | 169.2萬 USD | 99.5萬 USD |
| 折舊和攤銷 | 522.3萬 USD | 422.4萬 USD | 317.4萬 USD | 129.6萬 USD | 134.1萬 USD |
| 營業利益 | 728.4萬 USD | −1207.4萬 USD | −1015.8萬 USD | −675.5萬 USD | −385.4萬 USD |
| 淨利 | 497.3萬 USD | −1644.9萬 USD | 66萬 USD | −848.5萬 USD | −484.9萬 USD |
公司資料更新於 2026年8月24日。
財報歷史與展望
- EPS優於預期率
- 36%
- 優於預期4次、低於預期7次、符合預期0次
- 平均EPS意外幅度
- +17.21%
- 11 類似報告
- 最新每股收益結果
- -0.07
- 預估-0.02 · 低於預期250.00%
EPS:實際值與預估值
近期已公布業績
營收:實際值與預估值
近期已公布業績
分析師評級
第三方分析師預期可能變動,並非 GoAI 建議。
分析師目標價
平均目標
US$1.50
上漲空間 361.68%持有XTNT的ETF
報告持有此股票曝險的交易所交易基金。
繼續GoAI的研究
在 GoAI 中研究XTNTresearch.disclaimer

